Abstract
Cancer is a disease of ageing. There is scarce evidence to guide proper cancer treatment decisions for this population because older patients, especially those with age-related comorbidities, are under-represented in clinical trials [1]. During the past decades, there have been major breakthroughs in non-small cell lung cancer treatment. Up to half of the Asian patients with adenocarcinoma harbor epidermal growth factor receptor (EGFR) mutations – the predictive biomarker of EGFR tyrosine kinase inhibitors (EGFR TKIs) [2].
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
